(Carteolol hydrochloride + latanoprost) is a Small Molecule owned by Otsuka Pharmaceutical, and is involved in 1 clinical trial, which is ongoing.

Latanoprost is a prostaglandin F2a analogue. Latanoprost acts by binding to prostaglandin F2-alpha receptor and increases the flow of aqueous humor out of the eye, thereby reducing the pressure within the eye and reducing the risk of nerve damage and blindness. Latanoprost reduces intraocular pressure in glaucoma and ocular hypertension.

Carteolol is a beta1, beta2 and beta3 adrenergic receptor blocking agent. It has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by glaucoma.

The revenue for (Carteolol hydrochloride + latanoprost) is expected to reach a total of $641m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Carteolol hydrochloride + latanoprost) NPV Report.

(Carteolol hydrochloride + latanoprost) is currently owned by Otsuka Pharmaceutical. Otsuka Holdings is the other company associated in development or marketing of (Carteolol hydrochloride + latanoprost).

(Carteolol hydrochloride + latanoprost) Overview

Carteolol hydrochloride and latanoprost (Mikeluna) is a fixed dose combination in which Carteolol is a non-selective beta-adrenergic blocking agent and latanoprost acts as a anti hypertensive agent. It is formulated as solution for ophthalmic route of administration. Mikeluna is indicated for the treatment of glaucoma and ocular hypertension.

Otsuka Holdings Overview

Otsuka Holdings (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies. The company’s product portfolio includes pharmaceutical products, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices and OTC products. It markets its products in North America, Europe, and Asia. Otsuka is headquartered in Chiyoda-ku, Tokyo, Japan.

The company reported revenues of (Yen) JPY1,498,276 million for the fiscal year ended December 2021 (FY2021), an increase of 5.3% over FY2020. In FY2021, the company’s operating margin was 10.3%, compared to an operating margin of 13.8% in FY2020. In FY2021, the company recorded a net margin of 8.4%, compared to a net margin of 10.4% in FY2020. The company reported revenues of JPY451,811 million for the third quarter ended September 2022, an increase of 4.1% over the previous quarter.

Quick View – (Carteolol hydrochloride + latanoprost)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Carteolol hydrochloride + latanoprost)
Administration Pathway
  • Ophthalmic
Therapeutic Areas
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.